Neumora (NMRA) - Multiplikator forward rega marang pendapatan

Neumora Corp (NMRA) - logo korporat

The nearest growth catalyst for Neumora Therapeutics (NMRA) will be the results of the phase II trials for its innovative antidepressant. The forward P/S ratio visualizes this trend, where the mark indicates the current state of the metric. Business development relies on the precision of biomarker platforms and regulatory approval. The strategy's success is based on available R&D capital and the validation of schizophrenia treatment methods.

neumoratx.com - Rega forward marang dodolan NMRA (periode 04.07.2022 - 16.11.2026)

Rincian metrik komprehensif lan analitis Neumora Therapeutics (NMRA)

- indikator kapitalisasi pasar:
Analisis fundamental perusahaan:NMRA (Neumora Therapeutics, Inc.)
Produk asli Neumora Corp

When screening business quality, an investor evaluates the ratio of current market capitalization to expected revenue to determine the extent of the premium paid for future growth rates. This forward P/S valuation metric reflects the market multiple relative to projected sales, which for Neumora Therapeutics (NMRA) confirms a premium valuation driven by inelastic demand for precision neurobiology and the uniqueness of its genetic molecule-selection platform.

Pesaing langsung

Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CeriBell|Multiplikator Forward P/S Prothena Corporation plc|Rasio rega marang prakiraan pendapatan Alector Therapeutics (ALEC)|Annexon Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan omeros.com OMER|neurogene.com (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|acimmune.com - Multiplikator Forward P/S|Voyager Therapeutics Inc (VYGR) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S